An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

Vaccine

Volumn 25, Issue 4, 2007, Pages 741-750

  Palin, Amy ^a   Chattopadhyay, Anasuya ^a   Park, Steven ^b   Delmas, Guillaume ^b   Suresh, Rema ^b   Senina, Svetlana ^b   Perlin, David S ^b   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Plague vaccine; Vesicular stomatitis virus; Yersinia pestis

Indexed keywords

BACTERIAL PROTEIN; LOW CALCIUM RESPONSE PROTEIN V1; LOW CALCIUM RESPONSE PROTEIN V5; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; HUMORAL IMMUNITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PROVOCATION TEST; VACCINE PRODUCTION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS RECOMBINANT; YERSINIA PESTIS;

ADMINISTRATION, INTRANASAL; ANIMALS; FEMALE; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; PLAGUE; PLAGUE VACCINE; TIME FACTORS; VESICULAR STOMATITIS-INDIANA VIRUS; YERSINIA PESTIS;

EID: 33845210744     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.010     Document Type: Article

References (68)

1. Drancourt M., and Raoult D. Molecular insights into the history of plague. Microbes Infect 4 1 (2002) 105-109
2. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10 1 (1997) 35-66
3. Koornhof H.J., Smego Jr. R.A., and Nicol M. Yersiniosis II: the pathogenesis of Yersinia infections. Eur J Clin Microbiol Infect Dis 18 2 (1999) 87-112
4. Meyer K.F. Pneumonic plague. Bacteriol Rev 25 (1961) 249-261
5. Galimand M., Guiyoule A., Gerbaud G., Rasoamanana B., Chanteau S., Carniel E., et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337 10 (1997) 677-680
6. Greenfield R.A., and Bronze M.S. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents. Drug Discov Today 8 19 (2003) 881-888
7. Titball R.W., and Williamson E.D. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4 6 (2004) 965-973
8. Benner G.E., Andrews G.P., Byrne W.R., Strachan S.D., Sample A.K., Heath D.G., et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infect Immun 67 4 (1999) 1922-1928
9. Philipovskiy A.V., Cowan C., Wulff-Strobel C.R., Burnett S.H., Kerschen E.J., Cohen D.A., et al. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun 73 3 (2005) 1532-1542
10. Du Y., Rosqvist R., and Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 70 3 (2002) 1453-1460
11. Rodrigues C.G., Carneiro C.M., Barbosa C.T., and Nogueira R.A. Antigen F1 from Yersinia pestis forms aqueous channels in lipid bilayer membranes. Braz J Med Biol Res 25 1 (1992) 75-79
12. Williams Jr. R.C., Gewurz H., and Quie P.G. Effects of fraction I from Yersinia pestis on phagocytosis in vitro. J Infect Dis 126 3 (1972) 235-241
13. Friedlander A.M., Welkos S.L., Worsham P.L., Andrews G.P., Heath D.G., Anderson Jr. G.W., et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 21 Suppl 2 (1995) S178-S181
14. Fields K.A., Williams A.W., and Straley S.C. Failure to detect binding of LcrH to the V antigen of Yersinia pestis. Infect Immun 65 9 (1997) 3954-3957
15. Pettersson J., Holmstrom A., Hill J., Leary S., Frithz-Lindsten E., von Euler-Matell A., et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 32 5 (1999) 961-976
16. Price S.B., Leung K.Y., Barve S.S., and Straley S.C. Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis. J Bacteriol 171 10 (1989) 5646-5653
17. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., Kirschning C.J., et al. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 8 (2002) 1017-1024
18. Straley S.C., and Bowmer W.S. Virulence genes regulated at the transcriptional level by Ca2+ in Yersinia pestis include structural genes for outer membrane proteins. Infect Immun 51 2 (1986) 445-454
19. Anderson Jr. G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58 6 (1998) 793-799
20. Anderson Jr. G.W., Leary S.E., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64 11 (1996) 4580-4585
21. Andrews G.P., Heath D.G., Anderson Jr. G.W., Welkos S.L., and Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64 6 (1996) 2180-2187
22. Eyles J.E., Williamson E.D., Spiers I.D., and Alpar H.O. Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 18 28 (2000) 3266-3271
23. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 11-12 (1998) 1131-1137
24. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., and Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 63 8 (1995) 2854-2858
25. Miller J., Williamson E.D., Lakey J.H., Pearce M.J., Jones S.M., and Titball R.W. Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol 21 3 (1998) 213-221
26. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., Worsham P., et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21 5 (2005) 1490-1510
27. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12 3-4 (1995) 223-230
28. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15 10 (1997) 1079-1084
29. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19 4-5 (2000) 566-571
30. Williamson E.D., Sharp G.J., Eley S.M., Vesey P.M., Pepper T.C., Titball R.W., et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 14 17-18 (1996) 1613-1619
31. Garmory H.S., Freeman D., Brown K.A., and Titball R.W. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen. Vaccine 22 8 (2004) 947-957
32. Wang S., Heilman D., Liu F., Giehl T., Joshi S., Huang X., et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22 25-26 (2004) 3348-3357
33. Williamson E.D., Bennett A.M., Perkins S.D., Beedham R.J., Miller J., and Baillie L.W. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine 20 23-24 (2002) 2933-2941
34. Lawson N.D., Stillman E.A., Whitt M.A., and Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92 10 (1995) 4477-4481
35. Schnell M.J., Buonocore L., Whitt M.A., and Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70 4 (1996) 2318-2323
36. Kretzschmar E., Buonocore L., Schnell M.J., and Rose J.K. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71 8 (1997) 5982-5989
37. Roberts A., Buonocore L., Price R., Forman J., and Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73 5 (1999) 3723-3732
38. Dietzschold B., Rupprecht C.E., Fu Z.F., and Koprowski H. Rhabdoviruses. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields' virology (1996), Lippincott/Raven, Philadelphia 1137-1159
39. Rose J.K., and Whitt M.A. Rhabdoviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields' virology (2001), Lippincott Williams and Wilkins, Phhiladelphia
40. Zinkernagel R.M., Adler B., and Holland J.J. Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol 46 1-2 (1978) 53-70
41. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75 22 (2001) 11079-11087
42. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76 17 (2002) 8900-8909
43. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72 6 (1998) 4704-4711
44. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78 10 (2004) 5458-5465
45. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., et al. Development of a new vaccine for the prevention of lassa fever. PLOS Med 2 6 (2006) 537-545
46. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 7 (2005) 786-790
47. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 2 (2005) 174-182
48. Roberts A., Reuter J.D., Wilson J.H., Baldwin S., and Rose J.K. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78 6 (2004) 3196-3199
49. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 5 (2001) 539-549
50. Schlereth B., Rose J.K., Buonocore L., ter Meulen V., and Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74 10 (2000) 4652-4657
51. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20 9 (2004) 989-1004
52. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (2004) 3930-3940
53. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 79 24 (2005) 15043-15053
54. Rose N.F., Roberts A., Buonocore L., and Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74 23 (2000) 10903-10910
55. Fuerst T.R., Niles E.G., Studier F.W., and Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A 83 21 (1986) 8122-8126
56. Hill J., Leary S.E., Griffin K.F., Williamson E.D., and Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 65 11 (1997) 4476-4482
57. Lawton W.D., Erdman R.L., and Surgalla M.J. Biosynthesis and purification of V and W antigen in Pasteurella pestis. J Immunol 91 (1963) 179-184
58. Motin V.L., Nakajima R., Smirnov G.B., and Brubaker R.R. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 62 10 (1994) 4192-4201
59. Une T., and Brubaker R.R. Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol 133 4 (1984) 2226-2230
60. Une T., Nakajima R., and Brubaker R.R. Roles of V antigen in promoting virulence in Yersiniae. Contrib Microbiol Immunol 9 (1987) 179-185
61. Parent M.A., Berggren K.N., Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 73 11 (2005) 7304-7310
62. Green M., Rogers D., Russell P., Stagg A.J., Bell D.L., Eley S.M., et al. The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol 23 2 (1999) 107-113
63. Eyles J.E., Williamson E.D., Spiers I.D., Stagg A.J., Jones S.M., and Alpar H.O. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J Control Release 63 1-2 (2000) 191-200
64. Jones T., Adamovicz J.J., Cyr S.L., Bolt C.R., Bellerose N., Pitt L.M., et al. Intranasal Protollin trade mark/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 24 10 (2006) 1625-1632
65. Honko A.N., Sriranganathan N., Lees C.J., and Mizel S.B. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74 2 (2006) 1113-1120
66. Brubaker R.R. Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 71 7 (2003) 3673-3681
67. Nakajima R., Motin V.L., and Brubaker R.R. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 63 8 (1995) 3021-3029
68. Overheim K.A., Depaolo R.W., Debord K.L., Morrin E.M., Anderson D.M., Green N.M., et al. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73 8 (2005) 5152-5159